Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Propose...(d items Worldwide presence(1) of Apro...),Health

Worldwide presence(1) of Aprovel(R)/ Avapro(R)/ Karvea(R)

Change Change

on a on a

comparable comparable

euro million Q4 2007 basis FY 2007 basis

Europe 233 +1.7% 922 +5.1%

United States 129 +4.0% 507 +7.2%

Other Countries 118 +26.9% 422 +19.9%

TOTAL 480 +7.6% 1,851 +8.8%

Fourth-quarter worldwide sales of Aprovel(R)/Avapro(R)/Karvea(R) were euro 480 million, an increase of 7.6%.

In November, the United States Food and Drug Administration (FDA), based on efficacy data from two clinical trials involving over 1,200 patients with moderate or severe high blood pressure, approved Avalide(R) (irbesartan, hydrochlorothiazide) as the first combination therapy for initial use in patients likely to need multiple drugs to achieve blood pressure goals.

Net sales by division - Human Vaccines

Fourth-quarter consolidated net sales for the Human Vaccines business were down 15.3% at euro 649 million. This decrease reflects earlier shipments of influenza vaccines than in 2006, when a substantial proportion of shipments were delayed to the fourth quarter. As a result, net sales of influenza vaccines were down 40.4% at euro 245 million. Excluding influenza vaccines, net sales for the Human Vaccines business rose by 13.8% in the quarter.

Adacel(TM) (adult and adolescent tetanus-diphtheria-pertussis booster) and Menactra(R) performed very strongly in the fourth quarter, with net sales up 44.0% to euro 38 million and up 73.5% to euro 71 million respectively due to improved supply. An extension to the license for Menactra(R), covering children aged 2 to 10, was obtained in the United States in
'/>"/>